Stock CTBO CANTABIO PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cantabio Pharmaceuticals, Inc.

Equities

CTBO

US13808X2036

Market Closed - OTC Markets
Other stock markets
 14:08:59 2021-08-19 EDT 		5-day change 1st Jan Change
1.01 USD -95.96% Intraday chart for Cantabio Pharmaceuticals, Inc. -.--% -.--%
2019 Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate Researches the Therapeutic targeting of the DJ 1 Protein to Treat Immune Associated Diseases CI
2019 Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO from CTBOD CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cantabio Pharmaceuticals Receives Additional Grant from The Michael J. Fox Foundation for Testing Its Novel Redox DJ-1 Protein-based ELISA Platform for the Diagnosis of Parkinson's Disease
AQ
Cantabio Pharmaceuticals and Luxembourg Institute of Health Collaborate Researches the Therapeutic targeting of the DJ 1 Protein to Treat Immune Associated Diseases
CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO from CTBOD
CI
Cantabio Pharmaceuticals Inc. will Change its Ticker to CTBO.D from CTBO
CI
Cantabio Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended December 31, 2018
CI
Cantabio Pharmaceuticals Inc. Announces Expiration of Employment Agreement with Simon Peace as Chief Financial Officer
CI
Cantabio Pharmaceuticals Inc. Announces Resignation of Simon Peace from the Board
CI
Cantabio Pharmaceuticals Inc. Appoints Max Zhu as a Director
CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP
CI
Cantabio Pharmaceuticals Inc. to Present Positive in Vivo Efficacy Data in A Mice Model of Parkinson’S Disease from Its Dj-1 Protein Targeting Therapeutic Program At the Neuro4d Conference in Mainz, Germany
CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.3 million in funding from Yorkville Advisors Global LP
CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.3 million in funding from Yorkville Advisors Global LP
CI
Cantabio Pharmaceuticals, Inc. announced that it has received $0.6 million in funding from Yorkville Advisors Global LP
CI
Cantabio Pharmaceuticals Inc. to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimer's Disease At the 13th International Conference on Alzheimer's and Parkinson's Disease
CI
Cantabio Pharmaceuticals, Inc. announced that it expects to receive $0.6 million in funding from Yorkville Advisors Global LP
CI
Cantabio Pharmaceuticals Inc. Enters into a Licensing Agreement with Cambridge Enterprise Limited
CI
Cantabio Pharmaceuticals, Inc. to Present Results from its DJ-1 Protein Targeting Therapeutic Programs
CI
Cantabio Pharmaceuticals, Inc. and Purdue Research Foundation Sign Cooperation Agreement to Investigate the Targeting of DJ-1 Protein
CI
Cantabio Pharmaceuticals Inc. Announces the Development of Small Molecule Chaperones of the Abeta Peptide for the Treatment of Alzheimer's Disease in Collaboration with Novalix
CI
Gardedam Therapeutics, Inc. acquired Cantabio Pharmaceuticals Inc. in a reverse merger transaction.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CTBO Stock
  4. News Cantabio Pharmaceuticals, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW